The collector can change the receiving well or tube at preset time intervals, producing a regular sequence of eluate portions. Alternatively, a detector can trigger switching as components emerge from the separation system. These control modes let researchers choose between uniform time-based sampling and collection linked to detected elution behavior, depending on how they want to preserve differences among emerging components.
Components that leave the separation system at different times enter different labeled fractions, preserving their retention differences. Because each portion remains associated with its collection position, researchers can compare concentration, protein or metabolite content, and biological effects across the sequence. This positional information helps connect an observed cancer-relevant signal with the fraction in which it appears.
A biological effect can be tested fraction by fraction rather than only in the unfractionated sample. If one portion shows cytotoxicity or another cancer-relevant activity, its label identifies the corresponding chemical or molecular fraction for further characterization. The approach connects screening results with separation behavior, supporting the search for candidate therapeutic compounds.
Successive eluate volumes are directed into separately labeled wells or tubes as they emerge. The individual portions can then be screened for cytotoxicity, protein content, metabolite content, bioactivity, or other cancer-relevant signals. Keeping fractions separate allows each measured result to be related to its position in the sequence and to the material that emerged at that time.
This approach is useful when a sample must be examined across its separated components rather than as a single mixture. The workflow supports purification, biomarker characterization, and activity-guided identification of candidate therapeutic compounds. By preserving separate fractions, it enables researchers to investigate whether a cancer-relevant signal is associated with a particular portion of the separation.
Fraction-by-fraction screening can reveal where cytotoxicity, proteins, metabolites, bioactivity, or other cancer-relevant signals occur within the collected sequence. These results associate a measured property with a separated fraction rather than describing the sample only globally. That association can guide biomarker characterization or help identify molecular material linked to a potential therapeutic effect.